SOCS1, a novel interaction partner of p53 controlling











































SOCS1, cancer and senescence 
 
Cytokines are secreted proteins that regulate different 
cellular processes including survival, proliferation and 
differentiation. Following binding to their receptors, 
cytokines activate the Janus kinases (JAK1, JAK2, 
JAK3 and Tyk2) leading to the phosphorylation of 
tyrosine residues on the cytoplasmic portion of the 
receptor creating docking sites for signaling molecules 














































family of proteins that are recruited to the 
phosphorylated cytokine receptors themselves become 
phosphorylation substrates for JAK kinases. 
Phosphorylated STAT proteins homo- or hetero- 
dimerize and translocate to the nucleus to activate 
transcription of target genes by binding to specific 
response elements in their promoter regions. Among 
these cytokine-induced proteins, members of the SOCS 
family constitute important negative regulators of the 


























cytokine  signaling  to  activation  of  transcription,  are  frequently  activated  in  human  cancers.  Suppressors  of  cytokine
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proteins (CIS, SOCS1-7), each of which harbor a 
central SH2 domain and a C-terminal SOCS box region 
[3] (Figure 1). The suppressor of cytokine signaling 
SOCS1 was initially identified as a cytokine-inducible 
inhibitor of STAT signaling [4,5,6].  Through its SH2 
domain, SOCS1 can directly bind phosphorylated JAK2 
to prevent the phosphorylation of STAT. SOCS1 also 
possesses a kinase inhibitory region (KIR), a domain 
composed of less than 30 amino acids, which shares 
homology with the pseudosubstrate inhibitory region of 
JAK and leads to inhibition of the catalytic activity of 
JAK [7,8]. The SOCS box allows recruitment of elongin 
B/C and Cullin 2 to form an ubiquitin E3 ligase 
complex [9,10].  This allows the SOCS protein to 
operate as an adaptor to trigger ubiquitination and 
degradation of proteins involved in cellular signaling 
including JAK [11], TEL-JAK2 [12], IRS-1/2 [13], 
FAK [14], Vav [15] and Mal [16]. It is currently 
thought that SOCS1 contributes to tumor suppression 
due to its ability to control and terminate the activation 
of STATs [17,18,19,20,21,22,23,24,25]. On the other 































suppressor pathways and the cellular mechanisms by 
which SOCS1 might exert its tumor suppression remain 
largely unexplored. 
 
To prevent the formation of cancer, normal cells 
possess intrinsic tumor suppressor mechanisms that are 
triggered upon oncogene activation. Like apoptosis, 
cellular senescence opposes cellular transformation by 
limiting the proliferation of cells expressing oncogenes. 
In normal human diploid cells, oncogene activation 
causes a permanent growth arrest with features of 
cellular senescence [26]. We have recently extended the 
list of oncogenes known to trigger the senescence 
response to include the JAK/STAT5 pathway. The 
transcription factor STAT5 is implicated in tumor 
formation by regulating important cellular processes 
including cell cycle progression, apoptosis, 
angiogenesis and metastasis [27]. However, in normal 
cells, expression of Tel/Jak2 or constitutively activated 
allele of STAT5A and B initiated a cell cycle arrest in 
G1 associated with markers of premature cellular 
senescence and activation of the tumor suppressors Rb 
and p53 [28,29,30]. 
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 The activation of the p53 pathway following oncogene 
activation is crucial to induce senescence in normal 
cells. In mice, stimulation of p53 is dependent on 
p19ARF (Alternative Reading Frame), which is induced 
by several oncogenes [31,32]. However, the role of 
ARF in oncogene-induced senescence in human cells is 
still unclear [33]. In order to identify new regulators of 
p53 activation following constitutively activated 
STAT5 expression in normal cells, we performed 
microarray analysis covering the entire human 
transcriptome. We observed that the expression of 
SOCS1 was highly increased at both mRNA and protein 
level during STAT5-induced senescence [34]. 
Unexpectedly, SOCS1 expression in normal human 
fibroblasts was sufficient to trigger a p53-dependent cell 
cycle arrest displaying features of the senescence 
phenotype. This function of SOCS1 was dependent on 
the integrity of its SOCS box. In addition, SOCS1, but 
not a mutant lacking the SOCS box domain, led to the 
accumulation of phosphorylated p53 on serine 15 and 
increased transcription of the p53 target gene p21CIP. 
The knockdown of SOCS1 during STAT5-induced 
senescence reduced the phosphorylation of p53 on 
Ser15, diminished the nuclear accumulation of p53 and 
compromised the development of senescence phenotype 
[34]. The remaining activated p53 and partial bypass of 
the senescence response observed following the 
knockdown of SOCS1 might arise from the ability of 
STAT5 to engage multiple signaling pathways to ensure 
p53 activation. For example, STAT5 can directly 
transactivate the promoter of the PML gene and 
stimulate its expression in a p53-independent fashion 
[30].  The PML protein can then inhibit Mdm2 and 
stimulate p53 [35,36] contributing to the senescence 
phenotype [37,38]. 
 
SOCS1 mediated STAT5-induced senescence via an 
unexpected protein-protein interaction between the SH2 
domain of SOCS1 and the transactivation domain of 
p53 [34]. Because the transactivation domain of p53 
harbors no tyrosine residues, the binding should occur 
independently of tyrosine phosphorylation, as reported 
before for SOCS1 binding to Vav [15] and for other 
SH2 domains as well [39,40]. The von Hippel-Lindau 
protein (VHL), another SOCS box-containing protein, 
has been recently shown to interact with p53. This 
interaction does not rely on an SH2 domain but on the 
SOCS box domain of VHL. However, like SOCS1, 
VHL facilitates p53 interaction with the DNA damage 
activated kinase ATM [41]. Hence, SOCS1 links DNA 
damage signals stimulated by oncogenic activity to p53.  
 
Interestingly, SOCS1 is not the only protein inhibitor 
of STAT implicated in the regulation of p53 activity. 
The protein inhibitors of activated STAT, PIAS1 and 
PIASy both promote the sumoylation and trans-
criptional activity of p53 [42,43,44]. However, the 
mechanism of activation of p53 by PIAS is still 
unclear. While the sumoylation of p53 by PIAS1 has 
been demonstrated [43], a mutated PIAS1 lacking the 
RING finger-like domain and defective in promoting 
p53 sumoylation was sufficient to activate p53 [44]. 
Furthermore, by controlling the activity of both p53 
and Rb, PIASy regulates Ras-induced senescence and 
apoptosis [42]. These data suggest that the control of 
STAT signaling is tightly linked to the activation of 
p53 to possibly control the JAK/STAT oncogenic 
pathway. 
 
Inhibitors of STATs activity and the DNA damage 
response 
 
The stimulation of p53 during oncogene-induced 
senescence is associated with the activation of the DNA 
damage response [28,45,46]. The DNA damage 
observed in normal cells expressing activated 
oncogenes may be due to reactive oxygen species [47] 
and/or some type of replicative stress [45,46]. SOCS1-
induced senescence was accompanied by the activation 
of the DNA damage-regulated kinases ATM and Chk2. 
Since the stimulation of p53 reporters by SOCS1 was 
partially blocked in cells depleted of ATM, ATM might 
participate in the SOCS1-dependent activation of p53. 
Using pulldown assays, we demonstrated that SOCS1 
interacted with both ATM and ATR through its SOCS 
box (Figure 1) [34]. ATM is an important mediator of 
the senescence response by activating the p53 pathway, 
mainly through phosphorylation of the Ser 15 residue 
[28,45,46]. Depletion of SOCS1 during STAT5-induced 
senescence caused a dramatic decrease in Ser15 
phosphorylation of p53. In order to form a ternary 
complex with p53 and ATM, SOCS1 must localize to 
the nucleus. We confirmed that SOCS1 is able to 
localize to the nucleus and that endogenous SOCS1 
colocalized to DNA damage foci with ATM during 
STAT5-induced senescence [34], thus reinforcing the 
notion that SOCS1 is a mediator of the DNA damage 
response. Not only SOCS1 but also other proteins 
controlling JAK/STAT signaling are known to localize 
to DNA damage sites. PIAS1 and PIAS4 were also 
shown to localize to DNA breaks and contribute to the 
DNA damage response by sumoylating BRCA1 [48,49].  
Together, these findings strongly suggest a close link 





































Cytokines, senescence and SOCS1: an emergency 
switch to control proliferation 
 
Senescent cells secrete numerous cytokines and other 
mediators that modify the tissue microenvironment. The 
sum of these secreted factors constitutes what has been 
named the senescence-associated secretory phenotype 
(SASP) [50]. Among the SASP factors, IL-6 is required 
for the oncogene-induced senescence and induction of 
the tumor suppressor p15INK4B [51]. Furthermore, 
persistent, but not transient, DNA damage signaling 
triggers the ATM-dependent IL-6 secretion, presumably 
to call attention to the presence of damaged cells [52]. 
During oncogene-induced senescence, IL-6 also 
amplifies the secretion of IL-8 [51], which with GROα 
activates the CXCR2 receptor to reinforce senescence 
[53]. Among the factors secreted by senescent cells, 
IGFBP7 [54] and PAI-1 [55] contribute to the growth 
arrest response, while p53 regulates expression of 
chemokines directing the immune system to permit the 
clearance of senescent cells [56].  Collectively, these 
reports suggest that cytokine signaling could prevent 

































The capacity of SOCS1 to activate the p53 pathway can 
establish an emergency anti-proliferative program in 
cells exposed to sustain or aberrant cytokine stimulation 
(Figure 2). Following normal activation of the 
JAK/STAT pathway, SOCS1 blocks the phospho-
rylation of STAT by inhibiting or degrading JAK2. 
However, aberrant and sustained stimulation of STAT 
might induce a molecular switch allowing SOCS1 to 
localize to DNA breaks and stimulate ATM-dependent 
activation of p53. 
 
A general role for SOCS1 in the DNA damage 
response 
 
The localization of SOCS1 to DNA breaks during 
STAT5-induced senescence raises numerous questions. 
First, does the SOCS1 ubiquitin ligase activity 
contribute to the DNA damage response? A novel 
cascade of ubiquitination controlled by the E3 ubiquitin 
ligases RNF8/RNF168 and HERC2 have recently been 
reported to control the recruitment of BRCA1 and 
53BP1 by ubiquitinating the histones H2A and H2AX 
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activation but also control the DNA repair process. 
Second, what are the mechanisms underlying the 
nuclear transport of SOCS1 and its presence at DNA 
damage foci? Since most of its interacting partners were 
localized to the plasma membrane, SOCS1 was 
considered to be mostly a cytoplasmic protein, but 
recent evidences suggest that it can localize to the 
nucleus under certain conditions including STAT5-
induced senescence [34,63]. A bipartite nuclear 
localization signal (NLS) located between the SH2 
domain and the SOCS box allows nuclear localization 
of SOCS1 [63,64]. However, the mechanism controlling 
the active transport of SOCS1 remains unclear. A 
clearer understanding of the mechanisms controlling 
SOCS1 nuclear localization would be crucial to 
determine how SOCS1 mediates its tumor suppressor 
activity. Post-translational modifications like 
ubiquitination and phosphorylation that have been 
shown to control the nuclear localization of p53 
[65,66,67] and STAT [68] could also control the 
nucleo-cytoplasmic shuttling of SOCS1. Exclusion of 

































of the ternary complex with p53 and ATM, preventing 
the activation of p53. Furthermore, the phospho-
rylation status of SOCS1 could regulate its activity 
since aberrant SOCS1 phosphorylation is associated 
with cellular transformation. Actually, phospho-
rylation of SOCS1 triggered by the oncogenic v-Abl 
kinase impedes the SOCS1-Elongin B/C interaction, 
leading to sustained JAK/STAT signaling [69]. v-Abl 
signaling induces multiple serine/threonine kinases 
including members of the Pim kinase family. Pim-1 
and Pim-2 are required for efficient cellular 
transformation mediated by v-Abl [70] and are able to 
phosphorylate SOCS1 and disrupt its binding to 
Elongin C [71]. Because SOCS1 requires the SOCS 
box to form a complex with ATM, v-Abl- or Pim 
kinase-mediated phosphorylation could potentially 
interfere with this interaction and block p53 activation. 
Therefore, it appears that aberrant phosphorylation by 
oncogenic kinases could interfere with the tumor 
suppressor activities of SOCS1 by at least two 
different mechanisms: phosphorylated SOCS1 would 
not be able to inhibit the JAK/STAT pathway and to 



































Protein   Function 
Elongin C  Interacts with SOCS box [10] 
Elongin B  Interacts with SOCS box [10] 
Pericentrin  Cells depleted of pericentrin enter senescence due to p53 
activation [72] 
SHC (Src homology 2 domain containing) transforming 
protein 1 (SHC1) 
Member of the Shc protein family of molecular 
adaptors, SHC1 promotes apoptosis by its redox 
activity. SHC1 is implicated in the control of oxidative 
stress and life span in mammals [73].   
Tripartite motif-containing 28 (TRIM28 or KAP1)  TRIM28 is implicated in transcriptional control through 
its interaction with the Kruppel-associated box 
repression domain. TRIM28 contributes to DNA repair 
mechanisms [74]. 
5’-nucleotidase, cytosolic II (NT5C2)  NT5C2 hydrolyzes 5-prime-monophosphate (IMP) and 
other purine nucleotides. NT5C2 is implicated in the 
maintenance of a constant composition of intracellular 
purine/pyrimidine nucleotides [75]. 
BCL2-associated transcription factor 1 (BCLAF1)  BCLAF1, a transcriptional repressor that interacts with 
members of the BCL2 family of proteins, promotes 
apoptosis [76].  
Human positive cofactor 4 (PC4)  Suppressor of oxidative mutator phenotype [77]. 
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interactions of ATM and ATR with their targets suggests 
that other interaction partners of SOCS1 could also 
become the substrates of ATM/ATR-dependent phospho-
rylation during the DNA damage response. Proteomic 
analysis of SOCS1 complexes revealed putative 
interactions with several proteins that play a role in the 
DNA damage response, apoptosis or oxidative stress 
pathways (Table I). Future work will determine which 
functions of SOCS1 apply to every one of its interaction 
partners: ubiquitination followed by proteolytic 




Studies on molecular mechanisms underlying cellular 
senescence have made significant contributions to the 
discovery of novel regulators of tumor suppressor 
pathways. Using microarrays or cDNA / siRNA 
screens, multiple researchers have identified novel 
regulators of p53 or Rb in controlling tumor formation. 
Using this approach to study STAT5-induced 
senescence, we identified SOCS1 as an important 
activator of the p53 and the DNA damage response. 
Surprisingly, the SOCS box represents a binding motif 
for ATM and ATR [34]. To date, about 40 proteins are 
known to harbor a SOCS box domain. Clearly further 
work will determine whether SOCS box-containing 
proteins also participate in the DNA damage response 
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